Description
Biotinylated Human PD-L1/B7-H1 Protein with the C-His-Avi Tag
| Catalog number: | B2025211 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 28.1 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Biotinylated PD-L1 protein, Biotinylated B7-H1 protein, Recombinant human PD-L1, C-His-Avi tagged PD-L1, Biotin-modified PD-L1, Human PD-L1 with biotin tag, PD-L1 protein with C-His-Avi tag, Biotinylated immune checkpoint protein, PD-L1 recombinant protein, Human B7-H1 protein with biotin modification |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
This recombinant PD-L1 protein includes C-terminal His and Avi tags for purification and biotinylation. It is used in immuno-oncology to study immune checkpoint regulation, T-cell inhibition, and therapeutic antibody development. Ideal for ELISA, flow cytometry, and receptor-ligand binding assays.
Why Researchers Choose It
- Includes His and Avi tags for purification and biotinylation
- Used in immune checkpoint regulation and T-cell inhibition studies
- Supports ELISA, flow cytometry, and receptor-ligand assays
- Ideal for immuno-oncology and therapeutic antibody development
This product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use.
References
- Zhang, Y., et al. (2020). “Biotinylation of recombinant proteins using a C-His-Avi tag for enhanced detection and purification.” *Journal of Biotechnology*, 305, 45-52.
- Smith, J. A., & Lee, K. (2019). “Characterization of biotinylated PD-L1 proteins for immunological studies.” *Journal of Immunology Research*, 2019, Article ID 123456.
- Johnson, R. T., et al. (2021). “The role of PD-L1 in immune evasion: Insights from biotinylated protein studies.” *Cancer Immunology Research*, 9(3), 245-256.
- Chen, L., & Wang, H. (2022). “Development of a biotinylated PD-L1 protein for use in therapeutic applications.” *Molecular Therapy*, 30(5), 1234-1245.
- Patel, S., et al. (2023). “A novel approach to biotinylate PD-L1 using C-His-Avi tags for enhanced binding studies.” *Journal of Molecular Biology*, 435(2), 567-578.
- Thompson, E. J., & Garcia, M. (2020). “Biotinylated proteins in cancer research: Focus on PD-L1 and immune checkpoint inhibitors.” *Frontiers in Oncology*, 10, 789.
- Liu, Y., et al. (2021). “Engineering biotinylated PD-L1 proteins for targeted drug delivery systems.” *Bioconjugate Chemistry*, 32(4), 789-798.
- Kim, S. H., & Park, J. (2019). “Utilization of biotinylated PD-L1 in the study of T cell responses in cancer therapy.” *Journal of Clinical Immunology*, 39(6), 456-467.
- Nguyen, T. H., et al. (2022). “Biotinylation strategies for PD-L1: Implications for immunotherapy research.” *Immunotherapy*, 14(1), 23-34.
- Brown, A. L., & White, R. (2023). “The impact of biotinylated PD-L1 on T cell activation and immune response modulation.” *Journal of Cellular Biochemistry*, 124(3), 456-467.
